MedTrace Logo

Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.

NCT07550972 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-24

No results posted yet for this study

Summary

A single-arm, single-center clinical trial evaluating efficacy (Phase #)

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

A single-arm, single-center clinical trial evaluating efficacy

Combination therapy regimen: Pertuzumab combined with lenvatinib for neoadjuvant treatment Each 21-day period constitutes one treatment cycle, with pertuzumab administered at a dose of 3 mg/kg.(Up to 200 mg) Q3W, lenvatinib 8 mg QD.Total of 2-4 cycles.The subjects will undergo surgery subsequently. Subsequently, adjuvant therapy was administered.

Sponsors & Collaborators

  • Zhejiang Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Jiajie Xu · Zhejiang Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2030-03-31
Completion
2030-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07550972 on ClinicalTrials.gov